AMEDISYS INC (AMED) Stock Fundamental Analysis
USA - NASDAQ:AMED - US0234361089 - Common Stock
100.99 USD
+0.01 (+0.01%)
100.99 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to AMED. AMED was compared to 101 industry peers in the Health Care Providers & Services industry. AMED has an excellent profitability rating, but there are some minor concerns on its financial health. AMED has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
AMED had positive earnings in the past year.
AMED had a positive operating cash flow in the past year.
Of the past 5 years AMED 4 years were profitable.
Each year in the past 5 years AMED had a positive operating cash flow.
1.2 Ratios
AMED has a Return On Assets of 3.87%. This is in the better half of the industry: AMED outperforms 72.12% of its industry peers.
The Return On Equity of AMED (6.95%) is better than 66.35% of its industry peers.
With an excellent Return On Invested Capital value of 10.34%, AMED belongs to the best of the industry, outperforming 81.73% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMED is in line with the industry average of 9.33%.
The 3 year average ROIC (9.73%) for AMED is below the current ROIC(10.34%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROIC | 10.34% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
The Profit Margin of AMED (3.56%) is better than 68.27% of its industry peers.
AMED's Profit Margin has declined in the last couple of years.
AMED has a better Operating Margin (9.41%) than 78.85% of its industry peers.
AMED's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 43.19%, AMED is doing good in the industry, outperforming 71.15% of the companies in the same industry.
In the last couple of years the Gross Margin of AMED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
AMED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AMED has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMED has more shares outstanding
The debt/assets ratio for AMED has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.10 indicates that AMED is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.10, AMED is doing good in the industry, outperforming 75.00% of the companies in the same industry.
The Debt to FCF ratio of AMED is 1.55, which is an excellent value as it means it would take AMED, only 1.55 years of fcf income to pay off all of its debts.
AMED's Debt to FCF ratio of 1.55 is amongst the best of the industry. AMED outperforms 85.58% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that AMED is not too dependend on debt financing.
AMED's Debt to Equity ratio of 0.26 is fine compared to the rest of the industry. AMED outperforms 65.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Altman-Z | 4.1 |
ROIC/WACC1.2
WACC8.61%
2.3 Liquidity
A Current Ratio of 1.36 indicates that AMED should not have too much problems paying its short term obligations.
With a Current ratio value of 1.36, AMED perfoms like the industry average, outperforming 44.23% of the companies in the same industry.
A Quick Ratio of 1.36 indicates that AMED should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.36, AMED is in line with its industry, outperforming 50.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
AMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.24%, which is quite good.
Measured over the past years, AMED shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.46% on average per year.
Looking at the last year, AMED shows a small growth in Revenue. The Revenue has grown by 4.93% in the last year.
Measured over the past years, AMED shows a small growth in Revenue. The Revenue has been growing by 3.73% on average per year.
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
3.2 Future
The Earnings Per Share is expected to grow by 6.47% on average over the next years.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 4.95% on average per year.
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.26 indicates a rather expensive valuation of AMED.
Compared to the rest of the industry, the Price/Earnings ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 67.31% of the companies listed in the same industry.
AMED is valuated rather cheaply when we compare the Price/Earnings ratio to 27.40, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 19.15, which indicates a rather expensive current valuation of AMED.
Based on the Price/Forward Earnings ratio, AMED is valued a bit cheaper than 62.50% of the companies in the same industry.
AMED's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 |
4.2 Price Multiples
AMED's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AMED is cheaper than 65.38% of the companies in the same industry.
78.85% of the companies in the same industry are more expensive than AMED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.18 | ||
| EV/EBITDA | 11.63 |
4.3 Compensation for Growth
AMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y6.47%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
100.99
+0.01 (+0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.54%
Inst Owner Change-0.07%
Ins Owners1.88%
Ins Owner Change-34.96%
Market Cap3.32B
Analysts54.12
Price Target102.87 (1.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.78%
Min EPS beat(2)12.12%
Max EPS beat(2)13.43%
EPS beat(4)2
Avg EPS beat(4)-0.15%
Min EPS beat(4)-15.99%
Max EPS beat(4)13.43%
EPS beat(8)3
Avg EPS beat(8)-1.75%
EPS beat(12)6
Avg EPS beat(12)2.15%
EPS beat(16)9
Avg EPS beat(16)3.64%
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.01%
Revenue beat(8)2
Avg Revenue beat(8)-1.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.17%
Revenue beat(16)2
Avg Revenue beat(16)-2.65%
PT rev (1m)0%
PT rev (3m)0.02%
EPS NQ rev (1m)7.75%
EPS NQ rev (3m)3.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)0.63%
Revenue NQ rev (3m)-0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 | ||
| P/S | 1.38 | ||
| P/FCF | 14.18 | ||
| P/OCF | 13.87 | ||
| P/B | 2.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.63 |
EPS(TTM)4.75
EY4.7%
EPS(NY)5.27
Fwd EY5.22%
FCF(TTM)7.12
FCFY7.05%
OCF(TTM)7.28
OCFY7.21%
SpS73.04
BVpS37.47
TBVpS-1.84
PEG (NY)1.61
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROCE | 13.09% | ||
| ROIC | 10.34% | ||
| ROICexc | 12.85% | ||
| ROICexgc | 184.87% | ||
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% | ||
| FCFM | 9.75% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score6
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Debt/EBITDA | 1.13 | ||
| Cap/Depr | 8.5% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 8.42 | ||
| Cash Conversion | 83.2% | ||
| Profit Quality | 273.49% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z | 4.1 |
F-Score6
WACC8.61%
ROIC/WACC1.2
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y8.08%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year19.91%
EBIT Next 3Y9.46%
EBIT Next 5YN/A
FCF growth 1Y132.55%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y110.02%
OCF growth 3Y5.48%
OCF growth 5Y1.88%